Question · Q4 2025
John Franzreb asked about the impact of flu season normalcy on December 2025 volumes compared to December 2024, and the prospects for Q1 2026 growth given the tough Q1 2025 comparable. He also requested an update on the supply chain optimization process, inquired if M&A closure delays were due to rising multiples, and sought context on the unusual $1.2 million medical insurance costs incurred in Q4.
Answer
Carlos Quezada, CEO and Vice Chairman, explained that December 2025 saw increased volume due to a normal flu season, unlike December 2024 which pushed volume to January 2025. He noted that January 2026 volume was lighter year-over-year but strong cemetery performance and sales average per contract led to positive financial results. Steven Metzger, President and Secretary, confirmed Q1 2026 would be a tougher comparable. John Enwright, SVP and CFO, stated that supply chain optimization is in its early stages with more opportunities ahead, and clarified that M&A multiples remain steady, with delays attributed to seller readiness and selective acquisition criteria. Enwright and Quezada described the $1.2 million medical insurance cost as a 'one-off' large claim, unusual for the past two years, and confirmed it was factored into the 2026 guide.
Ask follow-up questions
Fintool can predict
CSV's earnings beat/miss a week before the call